Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT-MED
2024-518120-68-01Phase 2Authorised
- Sponsor
- Region Västra Götaland
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of degarelix in paraphilic disorder and hypersexuality (4 arms), sponsored by Region Västra Götaland. Planned start Apr 2026; status: authorised.
02
Drugs
degarelix
03
Conditions
paraphilic disorderhypersexuality
Beyond the preview
Go deeper on 2024-518120-68-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518120-68-01.